Long-Term Effect of Perindopril on Coronary Atherosclerosis Progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study)

American Journal of Cardiology

Volumn 100, Issue 2, 2007, Pages 159-163

  Rodriguez Granillo, Gastón A ^a   Vos, Jeroen ^c   Bruining, Nico ^a   Garcia Garcia, Hector M ^a   de Winter, Sebastiaan ^a   Ligthart, Jurgen M R ^a   Deckers, Jaap W ^a   Bertrand, Michel ^d   Simoons, Maarten L ^a   Ferrari, Roberto ^e   Fox, Kim M ^f   Remme, Willem ^b   De Feyter, Pim J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Sticares Cardiovascular Research Foundation   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d Lille Heart Institute   (France)

^e UNIVERSITY OF FERRARA   (Italy)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; PERINDOPRIL; PLACEBO; RAMIPRIL;

ADD ON THERAPY; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; ENDOSONOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERINDOPRIL; PROSPECTIVE STUDIES;

EID: 34447332268     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.02.073     Document Type: Article

References (21)

1. Hornig B., Kohler C., and Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95 (1997) 1115-1118
2. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C., Twigg S.M., Dilley R.J., Cooper M.E., and Allen T.J. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 (2002) 246-253
3. Powell J.S., Clozel J.P., Muller R.K., Kuhn H., Hefti F., Hosang M., and Baumgartner H.R. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (1989) 186-188
4. Hayek T., Hamoud S., Keidar S., Pavlotzky E., Coleman R., Aviram M., and Kaplan M. Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 43 (2004) 140-147
5. Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., and Teo K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103 (2001) 919-925
6. Hosomi N., Mizushige K., Ohyama H., Takahashi T., Kitadai M., Hatanaka Y., Matsuo H., Kohno M., and Koziol J.A. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 32 (2001) 1539-1545
7. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
8. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
9. Braunwald E., Domanski M.J., Fowler S.E., Geller N.L., Gersh B.J., Hsia J., Pfeffer M.A., Rice M.M., Rosenberg Y.D., and Rouleau J.L. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
10. Naccarella F., Naccarelli G.V., Maranga S.S., Lepera G., Grippo M.C., Melandri F., Gatti M., Pazzaglia S., Spinelli G., Angelini V., et al. Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality?. A critical review of controlled clinical trials. Curr Opin Cardiol 17 (2002) 6-18
11. Garg R., Yusuf S., and Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
12. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., Torp-Pedersen C., Ball S., Pogue J., Moye L., Braunwald E., and ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
13. Reiber J.H., Serruys P.W., Kooijman C.J., Wijns W., Slager C.J., Gerbrands J.J., Schuurbiers J.C., den Boer A., and Hugenholtz P.G. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 71 (1985) 280-288
14. De Winter S.A., Hamers R., Degertekin M., Tanabe K., Lemos P.A., Serruys P.W., Roelandt J.R., and Bruining N. Retrospective image-based gating of intracoronary ultrasound images for improved quantitative analysis: the intelligate method. Catheter Cardiovasc Interv 61 (2004) 84-94
15. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994) 633-638
16. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., and DeMaria A.N. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
17. Balk E.M., Karas R.H., Jordan H.S., Kupelnick B., Chew P., and Lau J. Effects of statins on vascular structure and function: a systematic review. Am J Med 117 (2004) 775-790
18. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
19. The Scientific Committee of the PERTINENT Sub-Study on behalf of the EUROPA-PERTINENT Investigators. PERTINENT-perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 17 (2003) 83-91
20. Bots M.L., Remme W.J., Luscher T.F., and Grobbee D.E. PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study-sub study of EUROPA: rationale and design. Cardiovasc Drugs Ther 16 (2002) 227-236
21. Bruining N., Hamers R., Teo T.J., de Feijter P.J., Serruys P.W., and Roelandt J.R. Adjustment method for mechanical Boston scientific corporation 30 MHz intravascular ultrasound catheters connected to a Clearview console. Mechanical 30 MHz IVUS catheter adjustment. Int J Cardiovasc Imaging 20 (2004) 83-91